Popular stacks

The community-named blends — honestly framed.

GLOW, KLOW, Wolverine, CagriSema, CJC + Ipamorelin — you’ll hear these names everywhere. Most are community formulations, not formally-studied combinations. We list them so you know what people are talking about, link out to each component’s evidence-tiered profile, and call out which stacks have actual trial data versus which are mechanism-plus-anecdote.

How to read these. A stack’s evidence is, by default, capped at its weakest component’s tier — there’s no separate trial of “GLOW.” Stacks marked Studied have been evaluated as a unit (e.g., CagriSema). Stacks marked Community are popular in self-experimenter circles but not formally trialed as a combination.

GLOW
Also known as: Skin & repair stack
Community blend
Skin, hair, and connective-tissue repair
Community-named blend that pairs a tissue-healing peptide (BPC-157), a fragment-derived recovery peptide (TB-500), and a copper-binding peptide with topical-evidence backing (GHK-Cu). Marketed by community vendors as a single injectable formulation; also assembled by users from individual vials.
Components
- BPC-157 →
  Tissue-healing peptide. Animal data is broad and consistent; human evidence is essentially absent. Tier 3.
- TB-500 →
  Thymosin Beta-4 fragment. Animal evidence for cell migration and angiogenesis. Frequently stacked with BPC-157. Tier 3 — and WADA-banned for competitive athletes.
- GHK-CU →
  Copper tripeptide. Tier 2 for topical skin and wound applications; Tier 3 for systemic injection. The topical evidence does not transfer to subQ.
Evidence note. There are no published trials of GLOW as a unit. Each component is tiered separately; the stack-as-a-blend inherits the weakest component's evidence. Vendor-formulated GLOW vials also lack independent characterization — purity and ratios vary by source.
Community dosing pattern. Typical community pattern: 250 mcg of each component, daily SubQ near the area of interest, for 4–6 week cycles. Highly variable across vendors and protocols.
Caveats
- Theoretical concern: BPC-157 and TB-500 both upregulate growth factors. Avoid in active malignancy.
- GHK-Cu's topical evidence does not justify the injectable concentration in most GLOW formulations.
- Vendor blends vary in component ratio — your 'GLOW' from vendor A may not match vendor B.
KLOW
Also known as: Gut healing stack
Community blend
Gut inflammation and intestinal permeability
Community-named blend that targets the gut. Most common formulation: KPV (anti-inflammatory tripeptide) + Larazotide (tight-junction modulator) + GHK-Cu (copper tripeptide) + BPC-157 (gastric pentadecapeptide). Vendor formulations vary; some omit Larazotide.
Components
- KPV →
  Lys-Pro-Val tripeptide derived from α-MSH. Anti-inflammatory; small but growing animal/human data on IBD.
- GHK-CU →
  Copper tripeptide. Anti-inflammatory + remodeling. Tier 2 topical / Tier 3 systemic.
- BPC-157 →
  Animal models of colitis and gastric ulcers show consistent mucosal healing. No human RCTs for IBD.
Evidence note. There are no RCTs of KLOW as a unit. Larazotide acetate is a separate clinical-stage molecule (originally trialed for celiac disease) and is not in this library; some KLOW formulations include it. The combined stack inherits the weakest component's evidence — currently Tier 3.
Community dosing pattern. Typical community pattern: 250–500 mcg of each peptide component, daily oral or SubQ, for 4–8 week cycles. Larazotide (when included) is taken orally before meals.
Caveats
- Larazotide is clinical-stage but not approved; safety in long-term off-label use is unestablished.
- Oral peptide bioavailability is generally poor — injectable formulations may have very different effects than the same components taken orally.
- Don't substitute KLOW for evaluation if you have unexplained GI symptoms; see a gastroenterologist first.
Wolverine
Also known as: BPC + TB stack, Recovery stack
Community blend
Tendon, ligament, and soft-tissue recovery
The simplest and most-discussed community recovery stack: BPC-157 + TB-500. Named after the Marvel character's healing factor. Marketed for post-injury recovery, tendinopathy, and post-surgical healing.
Components
- BPC-157 →
  Animal evidence for tendon-to-bone healing and ligament recovery. Tier 3.
- TB-500 →
  Animal evidence for cell migration and angiogenesis. Often dosed less frequently than BPC-157. Tier 3 — WADA-banned.
Evidence note. No human RCTs of either component, and none of the combination. The animal evidence for each is consistent within its model system; translation to human outcomes is not established. Athletes subject to WADA testing should not use TB-500.
Community dosing pattern. Typical pattern: BPC-157 250–500 mcg daily SubQ; TB-500 2–5 mg once weekly. Cycle length varies by user and indication.
Caveats
- TB-500 is WADA-banned year-round.
- Both peptides upregulate growth factors. Avoid in active malignancy.
- Preclinical-only evidence base — community efficacy reports are anecdotal.
CJC-1295 + Ipamorelin
Also known as: GH-axis stack, Sleep stack
Community blend
Endogenous growth hormone amplification
The dominant community GH-axis stack. Pairs a GHRH analog (CJC-1295) with a selective GHRP (Ipamorelin) — the two work on different receptors and produce a synergistic GH pulse when co-administered. Almost always dosed at bedtime, fasted.
Components
- CJC-1295 →
  GHRH analog. No-DAC form mimics natural pulses (multi-daily); with-DAC form sustains elevation (weekly).
- IPAMORELIN →
  Selective GHRP — minimal cortisol or prolactin elevation. Acts on the ghrelin receptor (GHSR), distinct from CJC-1295's GHRH receptor.
Evidence note. The combination is a community standard with strong mechanistic rationale (two different receptors → synergistic GH release). Published human studies of the combination as a unit are limited; component RCTs exist but are not typical-bodybuilding-protocol studies. Tier 3 for body-comp/longevity outcomes.
Community dosing pattern. Typical pattern: 100 mcg CJC-1295 (no-DAC) + 100 mcg Ipamorelin, SubQ at bedtime fasted. Some users add a third dose pre-workout. With-DAC variant is dosed weekly instead of nightly.
Caveats
- Avoid food (especially carbs/fats) within 2 hours of dosing — GH pulse is blunted by insulin.
- Long-term GH amplification effects on insulin sensitivity and cancer risk are not characterized.
- Tachyphylaxis is a real phenomenon with continuous GHRH analogs — most protocols cycle.
CagriSema
Also known as: Cagrilintide + Semaglutide
Studied as unit
Weight management — next-generation combination
Novo Nordisk's investigational fixed-dose combination of cagrilintide (amylin analog) and semaglutide (GLP-1 agonist). The amylin-axis amplifies satiety and slows gastric emptying on top of GLP-1 effects. Phase 3 (REDEFINE-1/2) is the headline weight-loss readout for this generation.
Components
- CAGRILINTIDE →
  Long-acting amylin analog. The 'cagri' half. Adds satiety + gastric emptying modulation distinct from GLP-1's incretin pathway.
- SEMAGLUTIDE →
  GLP-1 agonist. The 'sema' half. FDA-approved as Wegovy for chronic weight management.
Evidence note. Unlike the other entries on this page, CagriSema has been studied as a unit — Phase 2 and Phase 3 trials evaluate the fixed-dose combination directly. The combined evidence is Tier 1/2 (Phase 3 in flight as of early 2026). This is a 'studied' stack, not a community blend.
Community dosing pattern. Investigational protocol: weekly SubQ injection of the fixed-dose combination. Not commercially available outside trials; community 'CagriSema' attempts use separate vials of each component, which is NOT the same as the formal trial protocol.
Caveats
- The trial product is not commercially available. Self-mixing vials of cagrilintide and semaglutide does not replicate the studied formulation.
- GLP-1-class side effects compound: nausea, GI distress, gallbladder events.
- Monitor for hypoglycemia in patients also on insulin or sulfonylureas.

Looking to design your own stack? The stack builder walks you through goal-by-goal selection with sensible default doses pre-filled. Or browse the full peptide library and add components individually to your stack.